UNSPSC 51282919: Flumequine

This classification denotes a quinolone antibiotic with the molecular formula C14H12FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVG8VSP2SJ, chemically known as 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1h,5h-quinolizine-2-carboxylic acid but generally known as flumequine, which bears US NIH Compound Identifier 3374. European Medicines Agency schedules Flumequine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07696MIG.

UNSPSC 51282919 Flumequine, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally describes flumequine, a specific antimicrobial veterinary pharmaceutical, but the recent opportunities posted against this code are for naloxone, first aid supplies, multi-source generic pharmaceuticals, and direct-to-manufacturer prescription programs—none of which involve flumequine or match its scope. The mismatch suggests either tagging error in the source database or a jurisdictional classification system that does not align precisely with the UNSPSC taxonomy. State and local buyers do pursue pharmaceuticals, medical supplies, and emergency-response products regularly, but this code shows no current activity in its stated commodity.

The four posted opportunities span Florida, Texas, Minnesota, and regional cooperative purchasing structures, but none involve flumequine procurement. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 deadline; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 for direct-to-manufacturer prescription program information; the City of Tampa issued ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies to the Fire Department Rescue Division with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026. Given the absence of flumequine-specific activity and the categorical mismatch between the code and recent postings, this code does not merit pursuit under its stated scope.